CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 31 - 40 of 886
Study Number Lead Group Study Title CIRB Study Status
EA1183 ECOG-ACRIN FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE Adult CIRB - Late Phase Emphasis Available to Open
S1616 SWOG A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent Adult CIRB - Late Phase Emphasis Available to Open
GOG-0241 GOG A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Adult CIRB - Late Phase Emphasis Completed
NSABP-NCIC-CTG-MA.32.F NSABP Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1933 SWOG A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status Adult CIRB - Late Phase Emphasis Available to Open
RTOG-0534 RTOG A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy Adult CIRB - Late Phase Emphasis Available to Open
EA9161 Alliance A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) Adult CIRB - Late Phase Emphasis Available to Open
EA5142 ECOG-ACRIN Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Adult CIRB - Late Phase Emphasis Available to Open
S0221 SWOG Phase III Trial of Continuous Schedule AC+G Vs. Q2 Week Schedule AC; Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
NRG-GY009 NRG A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Adult CIRB - Late Phase Emphasis Available to Open
Displaying 31 - 40 of 886